SPARC's net loss widens to Rs 36 crore
SPARC reported widening of standalone net loss to Rs 36.41 crore for the first quarter ended June 30. The company had posted a net loss of Rs 1.65 crore for the corresponding period of the previous fiscal.
Sun Pharma Advanced Research Company (SPARC), the pharma research and drug discovery arm of Sun Pharma reported widening of standalone net loss to Rs 36.41 crore for the first quarter ended June 30.
The company had posted a net loss of Rs 1.65 crore for the corresponding period of the previous fiscal, SPARC said in a BSE filing.
It's standalone total income from operations for Q1FY17 has also declined by 50.55% to Rs 21.48 crore as against Rs 43.44 crore for the same period year ago.
SPARC also reported operating (EBITDA – earnings before interest tax depreciation and amortization) loss of Rs 36.11 crore.
Shares of Sun Pharma Advanced Research Company closed 3.70 per cent lower at Rs 361.80 on BSE.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
04:10 PM IST
Sun Pharma Advanced Research Q4 net loss widens to Rs 81.99 crore
SPARC signs licensing pact with Visiox Pharma for ophthalmic products